Abstract
Gene expression microarrays are a high-throughput, cost-effective method for measuring the expression of all genes in a sample. By comparing the expression patterns of healthy controls to diseased subjects, the genetic regulatory pathways underlying and affected by the disease can be elucidated. Furthermore, dysregulated genes are possible candidates for pharmaceutical therapy. Here, we consider the possibility of applying this approach to Tourette syndrome. We also review current theories of Tourette syndrome etiology and pharmacology.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 302-306 |
| Number of pages | 5 |
| Journal | Neurotherapeutics |
| Volume | 7 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jul 2010 |
Fingerprint
Keywords
- Gene expression
- Microarrays
- Pharmacology
- Tourette syndrome
ASJC Scopus subject areas
- Pharmacology (medical)
- Clinical Neurology
- Pharmacology
- Medicine(all)
Cite this
Tourette syndrome : Gene expression as a tool to discover drug targets. / Liao, Isaac H.; Sharp, Frank R.
In: Neurotherapeutics, Vol. 7, No. 3, 07.2010, p. 302-306.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Tourette syndrome
T2 - Gene expression as a tool to discover drug targets
AU - Liao, Isaac H.
AU - Sharp, Frank R
PY - 2010/7
Y1 - 2010/7
N2 - Gene expression microarrays are a high-throughput, cost-effective method for measuring the expression of all genes in a sample. By comparing the expression patterns of healthy controls to diseased subjects, the genetic regulatory pathways underlying and affected by the disease can be elucidated. Furthermore, dysregulated genes are possible candidates for pharmaceutical therapy. Here, we consider the possibility of applying this approach to Tourette syndrome. We also review current theories of Tourette syndrome etiology and pharmacology.
AB - Gene expression microarrays are a high-throughput, cost-effective method for measuring the expression of all genes in a sample. By comparing the expression patterns of healthy controls to diseased subjects, the genetic regulatory pathways underlying and affected by the disease can be elucidated. Furthermore, dysregulated genes are possible candidates for pharmaceutical therapy. Here, we consider the possibility of applying this approach to Tourette syndrome. We also review current theories of Tourette syndrome etiology and pharmacology.
KW - Gene expression
KW - Microarrays
KW - Pharmacology
KW - Tourette syndrome
UR - http://www.scopus.com/inward/record.url?scp=77954903756&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954903756&partnerID=8YFLogxK
U2 - 10.1016/j.nurt.2010.05.007
DO - 10.1016/j.nurt.2010.05.007
M3 - Article
C2 - 20643383
AN - SCOPUS:77954903756
VL - 7
SP - 302
EP - 306
JO - Neurotherapeutics
JF - Neurotherapeutics
SN - 1933-7213
IS - 3
ER -